慶應義塾研究者情報データベース

総合紹介 【 表示 ／ 非表示 】

総合紹介 【 表示 ／ 非表示 】

経歴 【 表示 ／ 非表示 】

経歴 【 表示 ／ 非表示 】

• 2023年04月

  -

  2025年03月

  医療法人社団　緑成会横浜総合病院, 薬剤部, 薬剤師

• 2025年04月

  -

  継続中

  慶應義塾大学 薬学部, 薬効解析学講座, 助教

学歴 【 表示 ／ 非表示 】

学歴 【 表示 ／ 非表示 】

• 2012年04月

  -

  2019年03月

  慶應義塾大学, 薬学部, 薬学科

  大学, 卒業

• 2019年04月

  -

  2023年03月

  慶應義塾大学大学院

  大学院, 卒業, 博士

学位 【 表示 ／ 非表示 】

学位 【 表示 ／ 非表示 】

• 博士（薬学）, 慶應義塾大学大学院, 課程, 2023年03月

免許・資格 【 表示 ／ 非表示 】

免許・資格 【 表示 ／ 非表示 】

• 薬剤師免許, 2019年05月

論文 【 表示 ／ 非表示 】

論文 【 表示 ／ 非表示 】

• Development and external validation of a population pharmacokinetic model and optimal Vancomycin dosing regimen for overweight and obese patients

  Komatsu T., Tomizawa A., Samura M., Suzuki A., Ishigo T., Fujii S., Ibe Y., Yoshida H., Tanaka H., Fujihara H., Yamaguchi F., Ebihara F., Maruyama T., Yagi Y., Hamada Y., Nagumo F., Takuma A., Chiba H., Nishi Y., Igarashi Y., Enoki Y., Otori K., Matsumoto K.

  Journal of Infection and Chemotherapy 31 （ 12 ） 102838 2025年12月

  研究論文（学術雑誌）, 査読有り,  ISSN  1341321X

  　概要を見る

  Introduction: This study aimed to develop and evaluate a population pharmacokinetic model and optimal dosing regimen for vancomycin in overweight and obese adults. Methods: A population pharmacokinetic model using a two-compartment system was constructed using a nonlinear mixed-effects approach, incorporating 527 data points from 184 participants. External validation of the model was carried out using an additional 55 data points from 21 participants; these were not used in the construction of the model. Monte Carlo simulations were used to determine the dosage that achieved the steady state area under the curve value falling between 400 μg h/mL and 600 μg h/mL. Results: In the final model, vancomycin clearance was found to be a significant predictor of blood vancomycin levels, alongside creatinine clearance (CCr), blood urea nitrogen levels, and incidence of heart failure. CCr was calculated with adjusted body weight (AdjBW). AdjBW was selected as a predictor of the volume of distribution in the central and peripheral compartments. External validation showed that the highest proportion of cases had deviations of less than 15 % between measured and predicted values in the final model developed in this study. This indicates that our model outperforms previously developed models (five for obese patients and four for non-obese patients). Conclusions: Our model shows that determining effective vancomycin doses for overweight and obese patients depend on estimated CCr rates, AdjBW, BUN levels, and incidence of heart failure.

  • Access to Document (DOI)

• Evaluating the necessity of two-point sampling for vancomycin area under the curve in follow-up therapeutic drug monitoring

  Suzuki A., Fujihara H., Yamaguchi F., Yoshida H., Tanaka H., Yagi Y., Maruyama T., Hamada Y., Ishigo T., Fujii S., Nagumo F., Samura M., Chiba H., Ebihara F., Takuma A., Komatsu T., Tomizawa A., Nishi Y., Igarashi Y., Enoki Y., Matsumoto K.

  Journal of Infection and Chemotherapy 31 （ 11 ） 102821 2025年11月

  研究論文（学術雑誌）, 査読有り,  ISSN  1341321X

  　概要を見る

  Objective: While both peak and trough (two-point) sampling are recommended to estimate the area under the concentration-time curve (AUC) for vancomycin, one-point sampling may reduce clinical burden. This study aimed to identify patient populations requiring two-point sampling by examining risk factors associated with AUC discrepancies between one- and two-point sampling during follow-up therapeutic drug monitoring (TDM). Method: This multicenter retrospective observational study included adult patients who received vancomycin from September 2020 to December 2023 and underwent two-point sampling at both initial and follow-up TDM. AUC was estimated using the Practical Antimicrobial TDM (PAT) version 4.0, and creatinine clearance (CLcr) was calculated using the Cockcroft-Gault equation. One- and two-point follow-up AUCs were compared using previously entered two-point concentrations from initial TDM. Patients were divided into a discrepancy group (AUC difference ≥10 %) and a non-discrepancy group. Risk factors were identified by univariate and multivariate analysis. Results: AUC values from one- and two-point sampling in 256 cases were highly correlated (r² = 0.965, p < 0.001). Seventeen cases (6.6 %) showed discrepancies ≥10 %. Multivariate analysis identified BMI ≥25 kg/m² (OR = 6.946, p = 0.001), CLcr <50 mL/min (OR = 5.863, p = 0.002), and ΔCLcr ≥10 mL/min (OR = 4.444, p = 0.012) as significant risk factors. Conclusion: Although one- and two-point AUCs showed strong correlation, discrepancies ≥10 % were more likely in patients with elevated BMI or impaired/unstable renal function. This suggests that two-point sampling may be essential for these patients to ensure accurate dosing of vancomycin during follow-up TDM.

  • Access to Document (DOI)

• Efficacy and safety of isavuconazole for invasive fungal infections: A systematic review and meta-analysis of randomized controlled trials

  Kawasaki A., Shintani R., Takao R., Nakazawa Y., Mihara T., Ikegami S., Shimada S., Matsumoto Y., Okamoto Y., Igarashi Y., Enoki Y., Taguchi K., Matsumoto K.

  Medical Mycology （Oxford University Press）  63 （ 10 ） myaf089 2025年09月

  研究論文（学術雑誌）, 共著, 責任著者, 査読有り,  ISSN  13693786

  　概要を見る

  Background Isavuconazole (ISA) is a treatment option for invasive fungal infections (IFIs) and is known for a favorable safety profile compared with other antifungal agents. However, comprehensive evidence regarding its efficacy and safety remains limited. Objectives This study aimed to assess the efficacy and safety of ISA compared with other antifungal agents through a systematic review and meta-analysis restricted to randomized controlled trials (RCTs), to provide more reliable estimates of its clinical effects. Methods Following Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) guidelines, a comprehensive literature search was conducted using PubMed, the Cochrane Library, Web of Science, and ClinicalTrials.gov to identify RCTs comparing ISA with other antifungal agents. The primary outcomes were clinical response and mortality. Secondary outcomes included the incidence of adverse events, including serious, drug-related, and organ-specific toxicities. A subgroup analysis was conducted focusing on filamentous fungal infections, comparing ISA and voriconazole. Results Three RCTs met the inclusion criteria. No statistically significant differences were observed between ISA and comparator agents in terms of clinical response, mortality, or total and organ-specific adverse events. A trend toward fewer adverse events was noted in the ISA group. In the subgroup analysis, ISA and voriconazole showed similar efficacy and overall safety; however, the incidence of both drug-related adverse events and hepatobiliary disorders was significantly lower in the ISA group. Conclusions ISA demonstrated efficacy comparable to that of other antifungal agents, with a favorable safety profile in patients with IFIs, including filamentous fungal infections. This meta-analysis of RCTs provides high-quality evidence to support antifungal drug selection in clinical practice.

  • Access to Document (DOI)

• Oral β-lactam combinations are effective in vitro against Mycobacterium avium, regardless of clarithromycin susceptibility

  Yoshikawa M., Nishimura T., Misawa K., Shimamura R., Suzuki K., Kashimura S., Igarashi Y., Enoki Y., Taguchi K., Hasegawa N., Namkoong H., Matsumoto K.

  Microbiology Spectrum 13 （ 11 ） e0201225 - 15 2025年09月

  研究論文（学術雑誌）, 共著, 査読有り

  　概要を見る

  The global incidence and prevalence of pulmonary disease caused by the Mycobacterium avium complex (MAC), mainly comprising M. avium and Mycobacterium intracellulare, is increasing. However, treating MAC pulmonary disease is challenging in cases of clarithromycin (CLR)-resistant MAC or where the patients experience adverse effects or drug interactions with the few available antibiotics. Therefore, developing novel and highly effective antibiotics against MAC is crucial. Although the efficacy of dual β-lactams against Mycobacterium abscessus has been receiving attention, the efficacy of dual β-lactams against MAC remains unclear. Here, we used MAC type strains and clinical isolates to determine whether dual β-lactams were effective against MAC and which combinations synergistically inhibited bacterial growth using a broth microdilution checkerboard assay with 6 oral and 22 intravenous antibiotics. The combination effect and antibacterial activity differed between M. avium and M. intracellulare. Five combinations of oral β-lactams and 78 combinations of intravenous β-lactams showed a synergistic effect against the M. avium type strain. Among the M. avium clinical isolates, faropenem combined with cefuroxime showed the highest synergistic effect, and amoxicillin combined with tebipenem showed the lowest minimum inhibitory concentration. There was no significant difference in the combination effects between the CLR-susceptible and CLR-resistant M. avium clinical isolates in these pairs. In conclusion, regardless of CLR susceptibility, the oral β-lactam combinations were effective against M. avium. Thus, when treating MAC pulmonary disease, it is crucial to determine whether M. avium or M. intracellulare is the cause. IMPORTANCE Mycobacterium avium complex causes chronic respiratory infections, but treatment is often limited by drug resistance, intolerance, or interactions. As new therapeutic strategies are urgently needed, we focused on β-lactam antibiotics, which are widely used and well tolerated. Although dual β-lactams are effective against Mycobacterium abscessus, their utility against Mycobacterium avium complex has remained largely unexplored. Our in vitro study revealed that several β-lactam combinations are effective against Mycobacterium avium, regardless of drug resistance, indicating potential for clinical use. In contrast, Mycobacterium intracellulare showed lower susceptibility to β-lactams. Given this difference in drug susceptibility, we emphasize the clinical need to distinguish Mycobacterium avium and Mycobacterium intracellulare to optimize treatment of Mycobacterium avium complex pulmonary disease.

  • Access to Document (DOI)

• External validation of a flowchart related to achieving the target area under the concentration-time curve for vancomycin: A retrospective multicenter study

  Ishigo T., Suzuki A., Ibe Y., Fujii S., Fukudo M., Yoshida H., Tanaka H., Fujihara H., Yamaguchi F., Ebihara F., Maruyama T., Yagi Y., Hamada Y., Samura M., Nagumo F., Komatsu T., Tomizawa A., Takuma A., Chiba H., Nishi Y., Igarashi Y., Enoki Y., Matsumoto K.

  Journal of Infection and Chemotherapy 31 （ 5 ） 102701 2025年05月

  研究論文（学術雑誌）, 査読有り,  ISSN  1341321X

  　概要を見る

  During therapeutic drug monitoring (TDM) for vancomycin (VCM), the area under the concentration-time curve (AUC) is important for balancing efficacy versus toxicity. In a previous study, we developed a decision tree (DT) model to achieve the target AUC during TDM over the follow-up period (AUCfollow-up). This study aimed to validate the DT model for achieving the target AUCfollow-up. Patients who received VCM for at least 72 h and had an initial TDM within four doses between January 2023 and December 2023 were analyzed. The AUC of the initial TDM was calculated over 2-point (peak/trough) concentrations via Bayesian estimation. The target AUCfollow-up was defined as 400–600 μg h/mL. Among 188 patients (median age [interquartile range], 66 [56, 79] years; 50 % female), the target AUCfollow-up was achieved in 70 % (132/188). When the predicted AUC was 400–600 μg h/mL, 84 % (102/121) achieved the target AUCfollow-up. In a 12 h dosing interval subgroup, 86 % (88/102) achieved the target AUCfollow-up. Conversely, when the predicted AUC was <400 or >600 μg h/mL, the proportion who achieved the target AUCfollow-up dropped to 44 % (30/67). Only 30 % (3/10) of those with creatinine clearance rates of >130 mL/min/1.73 m2 achieved the target. The area under the receiver operating characteristics curve was 0.74, and the R2 value was 0.15. Our findings confirmed the external validity of the DT model and supported its use for optimizing VCM dosing. Overall, the DT model offers a reliable framework for achieving target AUC values during follow-up for TDM, aiding safe and effective treatment.

  • Access to Document (DOI)

全件表示 >>

研究発表 【 表示 ／ 非表示 】

研究発表 【 表示 ／ 非表示 】

• 腎機能低下症例は2点採血でバンコマイシンのAUCを適切に調整することでAKIリスクを上昇させない

  石郷友之,鈴木絢子,藤居賢,伊部裕太,福土将秀,吉田博昭,田中宏明,海老原文哉,丸山拓実,八木祐助,佐村優,南雲史雄,小松敏彰,冨澤淳,詫間章俊,千葉博暁,五十嵐裕貴,榎木裕紀,浜田幸宏,西圭史,松元一明

  [国内会議]  第35回日本医療薬学会年会, 

  2025年11月

  , 

  口頭発表（一般）

• CREによる肺炎マウスモデルを用いたNAC/CFPM併用療法時の目標T＞MICi値

  水上雄貴,岡本侑子,五十嵐裕貴,榎木裕紀,田口和明,池上眞太郎,鈴木健太,高橋実秀,松元一明

  [国内会議]  第35回日本医療薬学会年会, 

  2025年11月

• ポサコナゾールの血清タンパク質への結合特性の解析

  岡本侑子,田口和明,五十嵐裕貴,榎木裕紀,松元一明

  [国内会議]  第35回日本医療薬学会年会, 

  2025年11月

  , 

  ポスター発表

• バンコマイシンの2回目TDMにおける2点採血の必要性

  鈴木絢子,藤原久登,山口史博,吉田博昭,田中宏明,八木祐助,浜田幸宏,石郷友之,藤居賢,南雲史雄,佐村優,千葉博暁,海老原文哉,丸山拓実,詫間章俊,小松敏彰,冨澤淳,西圭史,五十嵐裕貴,榎木裕紀,松元一明

  [国内会議]  第35回日本医療薬学会年会, 

  2025年11月

  , 

  口頭発表（一般）

• 炎症性腸疾患・Clostridioides difficile感染症マウスモデルを用いたfidaxomicinの有用性評価

  三原 貴之, 五十嵐 裕貴, 榎木 裕紀, 田口 和明, 松元 一明

  [国内会議]  第72回日本化学療法学会東日本支部総会 第74回日本感染症学会東日本地方会学術集会 合同学会 , 

  2025年09月

  , 

  口頭発表（一般）

全件表示 >>

競争的研究費の研究課題 【 表示 ／ 非表示 】

競争的研究費の研究課題 【 表示 ／ 非表示 】

• 瞬間的MICとHFIMを用いた感染部位指向型PK/PD評価手法の構築

  2025年04月

  -

  2027年03月

  文部科学省・日本学術振興会, 科学研究費助成事業, 研究活動スタート支援, 補助金,  研究代表者

• MA-T技術を活用した新規消毒剤の開発研究

  2025年

  -

  2026年03月

  一般用医薬品セルフメディケーション振興財団, 調査・研究助成, 補助金,  研究代表者

受賞 【 表示 ／ 非表示 】

受賞 【 表示 ／ 非表示 】

• 第8回フレッシャーズ・カンファランス優秀演題発表賞

  島村莉奈,西村知泰,吉川万衣子,三澤可奈,矢野大和,榎木裕紀,五十嵐裕貴,長谷川直樹,南宮湖,松元一明, 2025年06月, 抗菌薬投与が引き起こすMycobacterium abscessusの細胞壁脂質とコロニー形態変化

  受賞区分： 国内学会・会議・シンポジウム等の賞

• 日本化学療法学会Young Challenger Award（YCA）2025

  五十嵐裕貴, 2025年05月, 日本化学療法学会, β-ラクタム薬/β-ラクタマーゼ阻害薬の併用療法におけるin vivo pharmacokinetics/pharmacodynamics評価方法の構築

  受賞区分： 国内学会・会議・シンポジウム等の賞

• 第34回日本医療薬学会年会Postdoctoral award

  五十嵐裕貴, 2024年11月, 日本医療薬学会, β-ラクタム薬/β-ラクタマーゼ阻害薬の併用療法におけるin vivo pharmacokinetics/pharmacodynamics評価方法の構築

  受賞区分： 国内学会・会議・シンポジウム等の賞

• 2023年度KP会星野尚美記念薬学研究・活動奨励賞 研究論文部門

  五十嵐裕貴, 2024年, Development of an optimized and practical pharmacokinetics/pharmacodynamics analysis method for aztreonam/nacubactam against carbapenemase-producing K. pneumoniae

  受賞区分： その他

• Sato Pharmaceutical Research Encouragement Award

  五十嵐裕貴, 2020年, 佐藤製薬株式会社, PK/PD理論に基づくCefditorenの適正使用を目指したマウスにおける薬物動態研究

  受賞区分： その他

全件表示 >>

担当授業科目 【 表示 ／ 非表示 】

担当授業科目 【 表示 ／ 非表示 】

• 演習（薬効解析学）

  2025年度

• 卒業研究１（薬学科）

  2025年度

• 実務実習事前学習（実習）

  2025年度

• 英語演習（薬学科）

  2025年度

• 英語演習（薬科学科）

  2025年度

全件表示 >>

所属学協会 【 表示 ／ 非表示 】

所属学協会 【 表示 ／ 非表示 】

• 日本臨床薬理学会, 

  2025年01月

  -

  継続中

• 日本医療薬学会, 

  2021年02月

  -

  継続中

• 日本化学療法学会, 

  2019年11月

  -

  継続中